On May 22, 2017 IPHARMA received the Ministry of Health permission to conduct clinical trial of Phase I of the drug XC221. Protocol #ARI-XC221-01 "Double-blind randomized placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics...